Acumen rides aducanumab, amyloid and Alzheimer's waves on its IPO voyage

Acumen Pharmaceuticals is filing for a $100 million initial public offering hot on the heels of the FDA’s conditional approval of Biogen's controversial Alzheimer's disease drug Aduhelm (aducanumab).